Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

761P - Bowen’s disease and the risk of multiple primary skin malignancies

Date

07 Dec 2024

Session

Poster Display session

Presenters

Ekram Hasanin

Citation

Annals of Oncology (2024) 35 (suppl_4): S1679-S1697. 10.1016/annonc/annonc1699

Authors

E.H. Hasanin1, A. Ellaithy2

Author affiliations

  • 1 Medicine, University of Tripoli, 00218 - Tripoli/LY
  • 2 Faculty Of Medicine, Suez Canal University Hospital, 41522 - Ismailia/EG

Resources

This content is available to ESMO members and event participants.

Abstract 761P

Background

Bowen's disease (BD) is defined as an in-situ squamous cell carcinoma (SCC) of the epidermis. It has an incidence of 20-28 cases per 100,000 population per year. The major etiological factors of BD include ultraviolet light exposure, immunosuppression, and Human Papilloma Virus (HPV) infections. The development of melanoma, sarcoma, and non-epithelial skin as second primary malignancies (SPMs) following BD is a very unusual event rarely mentioned in the literature. No Studies discussed the association between Skin SPMs and BD. So, the purpose of this study was to evaluate the risk of all skin SPMs following BD across all age groups.

Methods

The Surveillance Epidemiology and End Result (SEER) database was used to obtain the data of patients diagnosed with BD from 2020 to 2021. We used MP-SIR session with multiple outcome analysis and the event was defined skin melanoma, Kaposi sarcoma and non-epithelial skin neoplasms. Excess absolute risk (EAR) was measured per 10,000. The Standardized Incidence ratio (SIR) was computed as observed/expected (O/E) with a 95% confidence interval (CI).

Results

Out of 1331 patients with BD, 15 patients developed skin SPMs. Kaposi sarcoma SPMs following BD had an O/E of 02.49 (P>0.05, EAR = -0.09) in the 2–11-month interval. Along a decade of follow-up, the O/E was 9.45 (P>0.05, 95%CI: 0.24 - 52.64, EAR = 0.62). There was a decreased risk of melanoma SPMs (P>0.05, 95%CI: 0.00-6.35, EAR = -5.30) in the 2–11 months interval while after 120+ months of follow-up, the O/E was 1.04 (P>0.05, 95%CI: 0.22–3.05, EAR = -0.31). The overall risk of developing additional non-epithelial skin SPMs had an O/E of 3.82 (P>0.05, 95%CI: 0.10-21.27, EAR = -1.54). For middle-aged, the risk of skin excluding basal and squamous SPMs had an O/E of 0.99 (P>0.05, 95%CI: 0.20-2.88, EAR = 0.04) while the elderly had an O/E of 0.36 (P>0.05, 95%CI: 0.04-1.30, EAR = -7.46).

Conclusions

The results of this study show BD had no significant risk to develop Kaposi sarcoma, melanoma and non-epithelial skin SPMs. Thus, decreasing the burden of skin SPMs among the survivors of BD and improving the psychological status. However, we recommend middle-aged and elderly to undergo routine follow up for the suspicious lesions putting into consideration the other risk factors associated with skin SPMs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.